Intravaginal immunization using a novel antigen delivery device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses

McKay, Paul F.; Mann, JF; Pattani, Aditya; Kett, Vicky L.; Malcolm, Karl; Shattock, RJ

doi:10.1186/1742-4690-9-s2-p191

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, IVRs can also be developed to allow the long-term delivery of heat-sensitive macromolecules, offering an attractive platform to develop vaginal mucosal vaccines for inducing vaginal mucosal immunity against HIV or direct delivery of HIV neutralization antibodies against HIV. McKay et al 37 recently described a novel antigen-releasing IVR capable of releasing human HIV-1 recombinant protein CN54gp140 and its adjuvant R848, yielding 30-fold increased mucosal immunoglobulin A response and higher amount of antigen-specific B cells in the genital draining lymph nodes of the sheep model.…”

Section: Intravaginal Ringmentioning

confidence: 99%

Current State of Microbicide Development

Traoré

Chen

2018

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Efforts in developing an effective vaccine for human immunodeficiency virus (HIV) has been challenging as HIV strains are highly variable and exhibit extraordinary mutability. Despite condom usage and pre-exposure prophylaxis as excellent prevention strategies, lack of accessibility in some developing countries and low adherence due to sociocultural factors continue to act as barriers in reducing the HIV epidemic. Microbicides are topical therapies developed to prevent HIV and other sexually transmitted infections during intercourse. Microbicides applied vaginally or rectally are intended to prevent HIV infection at the site of transmission by either inhibiting its entry into immune cells or prevent viral replication. This review will summarize some of the current state-of-the-art microbicide formulations that are in preclinical and clinical stages of development and discuss some of the challenges associated with microbicide development.

show abstract

Section: Intravaginal Ringmentioning

confidence: 99%

Current State of Microbicide Development

Traoré

Chen

2018

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…macrophages, CD8 + T cells) via coating the viral particles [16]. Several pre-clinical studies have demonstrated that significantly high levels of antigen-specific antibodies could be elicited using intravaginal immunization [17][18][19]. Broadly reactive NAb activity has been identified in a small number of HIV-1 infected subjects.…”

Section: Introductionmentioning

confidence: 99%

Fused deposition modeling three-dimensional printing of flexible polyurethane intravaginal rings with controlled tunable release profiles for multiple active drugs

Chen

Traoré

Walker

et al. 2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

We designed and engineered novel intravaginal ring (IVR) medical devices via fused deposition modeling (FDM) three-dimensional (3D) printing for controlled delivery of hydroxychloroquine, IgG, gp120 fragment (encompassing the CD4 binding site), and coumarin 6 PLGA-PEG nanoparticles (C6NP). The hydrophilic polyurethanes were utilized to 3D-print reservoir-type IVRs containing a tunable release controlling membrane (RCM) with varying thickness and adaptable micro porous structures (by altering the printing patterns and interior fill densities) for controlled sustained drug delivery over 14 days. FDM 3D printing of IVRs were optimized and implemented using a lab-developed Cartesian 3D printer. The structures were investigated by scanning electron microscopy (SEM) imaging and in vitro release was performed using 5 mL of daily-replenished vaginal fluid simulant (pH 4.2). The release kinetics of the IVR segments were tunable with various RCM (outer diameter to inner diameter ratio ranging from 1.12 to 2.61) produced from FDM 3D printing by controlling the printing perimeter to provide daily zero-order release of HCQ ranging from 23.54 ± 3.54 to 261.09 ± 32.49 µg/mL/day. IgG, gp120 fragment, and C6NP release rates demonstrated pattern and in-fill density-dependent characteristics. The current study demonstrated the utility of FDM 3D printing to rapidly fabricate complex micro-structures for tunable and sustained delivery of a variety of compounds including HCQ, IgG, gp120 fragment, and C6NP from IVRs in a controlled manner. Graphical abstract

show abstract

Intravaginal immunization using a novel antigen delivery device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses

Cited by 2 publications

References 0 publications

Current State of Microbicide Development

Current State of Microbicide Development

Fused deposition modeling three-dimensional printing of flexible polyurethane intravaginal rings with controlled tunable release profiles for multiple active drugs

Contact Info

Product

Resources

About